Do alternative capability instruments capture differing aspects of mental health and quality of life in comparison to the EQ-5D for schizophrenic patients with depression?

Timea Mariann Helter (timea.helter@muv.ac.at)  
Medical University of Vienna  https://orcid.org/0000-0002-2696-2553

Joanna Coast  
University of Bristol Medical School

Aga Łaszewska  
Medizinische Universität Wien

Tanja Stamm  
Medizinische Universität Wien

Judit Simon  
Medizinische Universität Wien

Research

Keywords: capability approach, psychometric validation, OxCAP-MH, ICECAP-A, EQ-5D-5L, schizophrenia, depression, mental health, quality of life, wellbeing, UK

DOI: https://doi.org/10.21203/rs.3.rs-44326/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background There is increasing evidence that assessing outcomes in terms of capability wellbeing provides information beyond that of health-related quality of life measures for evaluation in mental health research. This paper aimed to contribute to the utilisation of capability-based measures relative to health status measures in mental health research, by exploring the empirical relationship between the OxCAP-MH, the ICECAP-A, and the EQ-5D instruments against condition-specific measures and each other for schizophrenic patients with depression.

Methods Using trial data for 100 patients from the UK, the properties of the instruments were compared in terms of convergent validity, including correlations between the OxCAP-MH, the ICECAP-A, the EQ-5D-5L and the EQ VAS scores; and a line of central tendency between two variables was plotted on locally weighted smoothing curves. Exploratory factor analysis (EFA) investigated the extent to which the instruments measured complementary or overlapping constructs. Responsiveness was assessed in terms of standardised response mean and correlation between change scores (baseline to endpoint) of the instruments.

Results Correlation between the OxCAP-MH and ICECAP-A baseline scores was strong (0.677) and between change scores was moderate (0.388). The baseline scores of both capability instruments correlated more with condition-specific (0.481-0.718) than with generic (0.354-0.431) instruments. Change scores of the capability instruments weakly correlated with change scores of the generic health-related scales (0.131-0.269), but moderately with those of condition-specific instruments for the ICECAP-A (0.355-0.451) and moderately/strongly for the OxCAP-MH (0.437-0.557). The EFA found that while the EQ-5D-5L loaded onto one factor, the items of the ICECAP-A loaded onto two additional factors and the items of the OxCAP-MH loaded onto three additional factors.

Conclusions The capability instruments had stronger convergent validity with each other than with any of the other instruments. Assessing outcomes in terms of capabilities for schizophrenic patients with depression proved to capture broader relevant information than the EQ-5D-5L both by the OxCAP-MH and the ICECAP-A, albeit to different extents. When comparing the two capability instruments, the OxCAP-MH tended to have stronger correlations with condition-specific instruments most likely due to its origin from mental health outcome measurement, while the ICECAP-A had slightly stronger correlation with the EQ VAS. These capability measures provide a viable option for measuring outcome for economic evaluations of severe mental health conditions, and we would recommend the inclusion of OxCAP-MH and/or ICECAP-A alongside generic instruments such as the EQ-5D so that further evidence can be obtained.

Introduction

The capability approach was developed by Amartya Sen with a core focus on what individuals are free and able to do (i.e., capable of) (1, 2). This approach places emphasis on promoting wellbeing through enabling people to realise their capabilities and engage in behaviours that they value (3). There is increasing interest in the use of the capability approach for the economic evaluation of health-related interventions (4). One reason for this is the wider evaluative space this approach offers for the measurement of quality-of-life in comparison to the commonly used methods of assessing impacts in terms of health-related quality of life (HRQoL) (5). Currently the EQ-5D is the most commonly recommended and used HRQoL instrument (6, 7). However, the EQ-5D-5L may not capture important impacts of interventions when these go beyond health change and therefore underestimate their full welfare impact (8). Mental health care interventions usually target both health and social impairments because many people with severe and enduring mental illnesses experience significant functional and social challenges (9). Hence, their impacts go beyond HRQoL (10); particularly in the case of schizophrenia (11). People living with schizophrenia are more likely to be homeless, unemploying, or living in poverty compared with the general population; moreover, their disease is progressive and causes disability, dependence to care, and need for assistance of the surrounding people in daily life activities increases (12, 13). The prevalence of depressive disorder in schizophrenia has been reported to be around 50% (14, 15). Evidence suggests that depression is linked to poorer outcomes in schizophrenia, paired with particularly high levels of health care use and suicide (14-16).

The capability approach has been highlighted as a way of facilitating people with a lived experience of mental health difficulties to engage with their values and priorities (3). A recent literature review of capability instruments in economic evaluations of health-related interventions has identified 14 instruments, differing substantially in their development methods, domains, levels, target populations and interventions (4). Two of these instruments are commonly used and have been validated for the adult population with mental health problems: the Oxford CAPabilities questionnaire-Mental Health (OxCAP-MH) and the ICECAP measure for Adults (ICECAP-A). Both instruments have been shown to move beyond the standard HRQoL approach for the measurement and valuation of outcomes (5, 9, 17-24). While both instruments are grounded in the capability approach and have been implemented in the mental health context, their conceptual approaches differ. The OxCAP-MH was developed in the UK in the context of mental health outcome measurement using a top-down approach rooted in Nussbaum's central human capabilities free from geographical and cultural contexts. It was published in 2013 (9). The ICECAP-A belongs to a broader group of ICECAP capability instruments, each focusing on different aspects of capabilities according to a given life stage. It was also developed in the UK using bottom-up participatory (qualitative) methods to generate contextual capability attributes as recommended by Sen (25). The ICECAP-A was published in 2012.

Questions remain about whether different applications of the same broad concept of the capability approach result in similar or different measurement properties. Comparative studies of the measurement properties of alternative capability instruments have not been conducted yet, and researchers cannot rely on published studies when choosing between instruments. The lack of such comparative information hinders the future optimisation of research efforts related to quality of life and wellbeing in the (mental) health field.

Exploring the construct structures of and the convergence and divergence between the OxCAP-MH and the ICECAP-A measures would provide further information about their complementary or enhanced conceptual properties and contribute to our understanding of their pros and cons in certain contexts. Moreover, it may also shed light on some broader questions about how each method of instrumentalising the capability theory influences measurement processes. Additionally, the hypothesis that capability instruments, regardless of using a top-down or bottom-up approach to their development, are more correlated to each other than to a HRQoL instrument, e.g. EQ-5D-5L or EQ VAS, has not been tested before in the area of mental health. Laszewska et al. found...
that all EQ-5D-5L items and seven OxCAP-MH items loaded on one factor and nine remaining OxCAP-MH items loaded on a separate factor, indicating that the OxCAP-MH may be seen as supplementary rather than complementary in its concept, when compared to the EQ-5D-5L [5]. Previous factor analysis comparing the ICECAP-A with the items of EQ-5D-5L [51] and EQ-5D-3L [18, 20] found that these instruments measure two different constructs and therefore provide potentially different information. A recent systematic literature review found inconsistencies between the ICECAP-A and EQ-5D instruments, suggesting that the ICECAP-A is most appropriately regarded as a complement for and not a substitute to the EQ-5D-3L and EQ-5D-5L in particular [36]. In addition, capability instruments have only been compared to a limited number of condition-specific mental health instruments [17, 26].

This paper aimed to contribute to the utilisation of capability-based measures relative to health status measures in mental health research, by exploring the empirical relationship between the OxCAP-MH, the ICECAP-A, and the EQ-5D instruments against condition-specific measures and each other for schizophrenic patients with depression. We conducted analyses to assess the measures': (1) convergent validity, based on the strength and statistical significance of correlations, using statistical and graphical methods; (2) construct validity by using exploratory factor analysis (EFA) to assess the underlying construct of the measures; and (3) responsiveness, based on Spearman's rank correlations between change scores of instruments. The findings of this study should provide relevant information for researchers and decision-makers on how to optimise future quality-of-life information collection given a patient population similar to our study.

Methods

Data source

The analysis in this paper was based on data from the PoMeT trial (15), which investigated the impact of Positive Memory Training on depression symptoms of schizophrenia patients (n=100) in the UK between 2014-2016. The trial received ethical approval from the Berkshire Research Ethics Committee (REC ref 13/SC/0634). Patients were eligible for inclusion if they were between 18-65 years of age, had a DSM-V diagnosis of schizophrenia or schizoaffective disorder, and had at least a mild level of depression as measured by scoring 14 or more on the Beck Depression Inventory-II (27). Participants were identified by trial research assistants, working in collaboration with care coordinators based within community mental health teams. Randomisation was stratified by site and severity of depression (above and below a BDI-II score of 29, i.e. a severe level of depression) using randomised-permuted blocks (15). Patients were assessed at four time points through the 9-month study period: baseline, 3 months, 6 months and 9 months. More details about the PoMeT trial can be found in Steel et al (15).

Instruments

The OxCAP-MH is a self-reported, 16-item instrument developed in the context of mental health outcome measurement, where items are rated on a 1–5 Likert-scale and each question provides an equal contribution to the overall score. The 16 items cover a broad range of individual wellbeing aspects including: overall health, Enjoying social and recreational activities, Losing sleep over worry, Friendship and support, Having suitable accommodation, Feeling safe, Likelihood of discrimination and assault, Freedom of personal and artistic expression, Appreciation of nature, Self-determination and Access to interesting activities or employment (9). The OxCAP-MH initial score (16-80 scale) is converted on to a 0–100 scale referring to minimum and maximum capabilities using the formula: 100 × (OxCAP-MH total score – minimum possible score)/possible range (17). Higher scores indicate better capabilities; items 2, 4, 5, 6, 9, 10, 11, 12, 13, 14, 15 and 16 are reverse coded. The OxCAP-MH has shown validity (5, 17), responsiveness (5, 17) and feasibility (9) in several settings and mental health disease areas, including schizophrenia and depression (14, 15, 24). It is currently available in the English, German (28), Hungarian (29) and Luganda languages with further language translations ongoing. The OxCAP-MH does not yet have a preference-based value set, so far it has been used in economic evaluations as a score; however, research is on-going to develop a weighting system for its domains.

The ICECAP-A is a brief self-reported measure for the general adult population with five items, each of which can take one of four levels ranging from full capability to no capability. The domains include Stability (being able to feel settled and secure), Attachment (being able to have love, friendship and support), Autonomy (being able to be independent), Achievement (being able to achieve and progress), and Enjoyment (being able to have enjoyment and pleasure) (18). The ICECAP-A has shown validity (22, 23, 25, 30, 31) reliability (32, 33), responsiveness (34) and feasibility (20) in different populations, including depression (35). Beside the original English language version, it is also available in German (32), Chinese (36), Welsh, Dutch, Danish, Persian and Italian languages (37). The ICECAP-A has a preference-based value set derived from the UK general population (30) and it is increasingly used in economic evaluations (38). The preference-based scores of the ICECAP-A range between 0 and 1.

The EQ-5D is one of the most commonly used self-reported generic health status measures, and its validity and reliability have been reported in various health conditions and populations (39). The EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Beside the original 3-level version (40), a more sensitive, 5-level version exists since 2009 (41), and both versions have value sets developed in several countries (42). This study used the UK value set developed for the EQ-5D-5L. As part of the EQ-5D-5L, respondents' self-rated health is also recorded on a vertical visual analogue scale (EQ VAS) where scores range between 0-100 referring to worst imaginable health state and best imaginable health state, respectively. The EQ VAS can capture further important, complementary information to the health state information patients provide when they self-report their health on the EQ-5D descriptive system (43).

The analysis also included comparative information from four condition-specific instruments used in the POMET trial due to their ability to capture important aspects of the condition from the patient's perspective and thereby enabled the assessment of the OxCAP-MH, ICECAP-A, and EQ-5D-5L instruments' ability to
reflect clinically relevant mental health outcomes. The Beck Depression Inventory (BDI), General Anxiety Disorder (GAD), Rosenberg self-esteem scale (RSES), and the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) are all mental-health specific, self-reported measures.

BDI is a self-reported measure of depressive symptoms and their severity in adolescents and adults according to the Diagnostic and Statistical Manual for Mental Disorder (44). It has 21-items scored on 4-point polytomous response scale ranging from 0 to 3 (27). Scores range between 0 and 63 with higher score representing more severe depression.

GAD is a self-reported measure of anxiety symptoms over the last two weeks. It consists of seven items scored on a 0-3 scale with higher score indicating more severe symptoms (range from 0 to 21) (45). The cut-off scores of 5, 10 and 15 reflect mild, moderate and severe anxiety symptoms, respectively (46).

RSES is a 10-item, self-reported instrument that measures global self-worth by measuring both positive and negative feelings about the self (47). Items are answered using a 4-point polytomous response scale format ranging from strongly agree to strongly disagree. Items 2, 5, 6, 8, 9 are reverse scored.

The self-reported WEMWBS instrument was developed in the UK to assess mental wellbeing including affective-emotional aspects, cognitive-evaluative dimensions and psychological functioning. It is a 14-item scale with 5 response categories (‘none of the time’, ‘rarely’, ‘some of the time’, ‘often’, ‘all of the time), with a total score ranging from 14–70. A higher score indicates a higher level of mental wellbeing (48).

Statistical analysis

The statistical analysis focused on exploring and comparing the measurement properties of the OxCAP-MH, ICECAP-A, EQ-5D-5L and the EQ VAS. Correlations of baseline scores to test and compare construct validity across the scales, exploratory factor analysis (EFA) and investigation of responsiveness to change were carried out. To better understand how these instruments perform, Appendix 1 demonstrates the floor and ceiling effects observed with the four scales.

For all analyses, the level of significance was determined at p < 0.05, unless stated otherwise. Group comparisons of mean baseline scores were conducted using the Wilcoxon rank-sum test (49, 50) for two-group comparisons and Kruskal-Wallis one-way ANOVA for multiple group comparison (51). Analysis was conducted on complete cases, excluding missing items at the relevant time point, unless stated otherwise. EFA was conducted with the freely available FACTOR software, and we used STATA Version 16 for all other analyses.

Convergent validity

Convergent validity indicates the degree to which two measures of constructs that theoretically should be related, are in fact related (52, 53). The hypothesis, that capability instruments and their items have stronger correlation with each other than with a HRQoL instrument, was tested through exploring the correlation between baseline scores. Spearman’s rank correlations across OxCAP-MH, ICECAP-A, EQ-5D-5L, EQ VAS and condition-specific measures were calculated at total score-level at baseline and assessed based on Cohen’s effect size classification, namely < 0.3 is small, 0.3 - < 0.5 is moderate and ≥ 0.50 is large (54).

Next, locally weighted smoothing curve (LOWESS) fit lines were used to graphically indicate nonlinear trends in the scatter plots between OxCAP-MH, ICECAP-A, EQ-5D-5L and EQ VAS scores (55). LOWESS is a form of nonparametric regression that plots a line of central tendency between two variables on a scatterplot, thereby visualizing the relationship across the possible score ranges. LOWESS captures general patterns in the relationship between two measures without making assumptions about their actual relationship (56).

Exploratory factor analysis

EFA is a method to uncover the underlying structure of variables and is therefore used to assess whether an instrument measures what it intends to measure (57). It was used to evaluate the construct validity through the factors (or concepts) assessed by the instruments and their relevance to the underlying construct. EFA was conducted on the baseline scores of the OxCAP-MH, ICECAP-A and EQ-5D-5L to examine the overlap between the constructs of the two capability measures and the multidimensional measure of HRQoL, and to study how far they share the same set of underlying factors. This was examined through factor loadings, which can range from -1 to 1. Loadings close to -1 or 1 indicate that the variable strongly influences the factor, whilst 0 indicates low influence. Further details on the methods of EFA can be found in Appendix 3.

Responsiveness
Responsiveness was defined as the ability to capture clinically important changes over time (58). Patients filled out each scale at both baseline and 9 months, which allowed for an exploration of change in mean scores over time across all instruments. Responsiveness was assessed by Spearman’s rank correlation between baseline to endpoint change scores.

Results

Patient characteristics

The mean age of respondents was 43 years (SD: 10.55). Further patient characteristics are presented in Table 1.

Convergent validity

Mean baseline scores for all instruments used in this analysis and their correlations are presented in Table 2. Graphical presentation of baseline correlations are included in Appendix 2.

Spearman’s rank correlations at baseline confirmed the hypothesis that the capability instruments are more correlated with each other than with the EQ-5D-5L or the EQ VAS. Correlations between the capability and HRQoL measures (0.354-0.431) were lower than those between OxCAP-MH and ICECAP-A (0.677). The ICECAP-A was slightly more correlated with EQ VAS (0.431) than with the EQ-5D-5L (0.364), whilst the OxCAP-MH was somewhat higher correlated with the EQ-5D-5L (0.406) than with the EQ VAS (0.354). The baseline scores of both capability instruments were higher correlated with condition-specific (0.481-0.718) than with generic (0.354-0.431) instruments.

The scatter plots with the LOWESS lines visualising the relationship between the instruments are presented in Figures 1a-1f. The LOWESS lines’ stagnating or upward trend indicates that, as expected, a higher score (better state) in one instrument tends to be associated with higher or unchanged score on the other scales. This indicates that the capability and HRQoL instruments share a general broad pattern in capturing the full welfare impact of mental health care. However, the most fluctuating trend could be observed between the OxCAP-MH and ICECAP-A instruments, suggesting that the alternative capability measures might capture differing aspects of mental health and quality of life.

Exploratory factor analysis

A four-factor solution was chosen according to the Kaisers criterion based on a scree plot, as described in Appendix 3. EFA with four factors found that all items of the instruments had communalities greater than 0.35, i.e. none of the items struggled to load significantly on any factor. Hence, the factor loadings are shown in Table 3 for any factor >0.35.

Factor one consisted of the five EQ-5D-5L domains, with particularly high communalities for all items apart from the Anxiety/Depression domain. The Limit daily activities and Suitable flat situation domains of OxCAP-MH and the Being independent domain of ICECAP-A also loaded to this undoubtedly HRQoL-related factor. None of the EQ-5D-5L domains loaded on factors two, three and four, thereby suggesting that these factors capture capability-related concepts. Only the Feeling settled and secure domain of ICECAP-A loaded on factor two, where high communalities were observed for the domains of OxCAP-MH related to the perception of the settlement and security, e.g. Less sleep over worries, Safety in neighbourhood, Probability for assault and Probability of discrimination. The negative loading of Access to interesting activities/employment is consistent with the direction of scoring of the items. Factor three consisted of four ICECAP-A domains (the Being independent domain did not load on this factor) and the Meet socially with friends and family, Enjoy free time activities, Local decisions, Freedom of expression, Enjoy love and Support and Freedom of deciding for yourself domains, Creativity and Access to interesting activities/employment domains of OxCAP-MH.

Factor four consisted of two OxCAP-MH domains, both focusing on the appreciation of a person’s environment. These two domains had remarkably high communalities on factor four and did not load to any other factor.

Responsiveness

The Spearman’s rank correlation between the baseline to endpoint change scores of the OxCAP-MH, ICECAP-A, EQ-5D-5L and EQ VAS, and the potential reference instruments are presented in Table 4.
Correlation between the OxCAP-MH and ICECAP-A change scores was moderate (0.388). The ICECAP-A change scores weakly correlated with change scores of generic health-related scales (0.247-0.269), whilst moderate correlations were observed in case of self-reported condition-specific instruments (0.355-0.451). The OxCAP-MH change scores had weak correlation with generic scales (0.131-0.203), but moderate to high correlation with self-reported condition-specific instruments (0.440-0.557). Overall, the OxCAP-MH showed stronger responsiveness in relation to changes in depression, anxiety and mental health as measured by the BDI, GAD, RSES and the WEMWBS than the ICECAP-A.

Discussion

This paper aimed to contribute to the utilisation of the capability approach in mental health by empirically demonstrating that two instruments embedded in the capability framework may show somewhat different psychometric properties when deployed on the same patient cohort. This could be explained by their different approaches to development, namely that the OxCAP-MH followed a more top-down approach, whilst the ICECAP-A followed a bottom-up method. The findings of this study could be used as guidance when optimising instrument selection for economic evaluations or other types of assessment in this context. To our knowledge, this is the first paper to empirically compare the two most commonly used capability instruments in the area of mental health and compare them simultaneously to condition-specific and generic HRQoL scales. In particular, this paper further confirmed the construct validity of both OxCAP-MH and ICECAP-A questionnaires as instruments measuring capabilities. At baseline, the two capability instruments were strongly correlated with each other, but moderately correlated with the EQ-5D-5L and EQ VAS. Overall, both scales were also stronger correlated with self-reported measures of general mental health wellbeing (e.g. WEMWBS) and instruments measuring depressive symptoms (assessed with BDI) and self-worth/self-esteem (assessed with RSES) than the two measures of HRQoL.

Capability instruments may be seen as supplementary rather than complementary in their concept and their evaluative space captures more of what might be important for those with this condition because their correlation to self-reported condition-specific instruments is stronger. The LOWESS plots across the OxCAP-MH, ICECAP-A and EQ-5D-5L instruments showed that a higher score in one scale tends to be associated with higher or unchanged score on the other scales. This confirmed that the capability and HRQoL instruments share a general broad pattern in capturing the full welfare impact of mental health care. However, the results of the EFA of the items of both capability instruments and the EQ-5D-5L demonstrated that the capability instruments measure concepts beyond the standard interpretation of health because all items of the HRQoL measure loaded onto one factor, whilst the capability instruments spread across multiple factors. The results of the EFA suggested that the four factors represent different aspects of wellbeing measurement. Factor one could be linked to HRQoL, but also including independence and suitable accommodation which suggests an interesting link between these domains. Factors two, three and four seemed to include capability-specific domains. Factor two included items related to settlement and security aspects, where the negative loading of access to interesting activities indicates that this might be an auxiliary concept. Most of the OxCAP-MH and ICECAP-A items loaded on factor three, which could be interpreted as the internal psycho-social aspect of capabilities. These alternative loadings to factors two and three demonstrated the difference between the internal and external aspects of freedom within the capability approach. The findings of the current study were in line with a qualitative validation study of the Hungarian version of the OxCAP-MH, i.e. most domains in factor two and four of the EFA in this study were associated with the internal aspects of freedom, whilst factor three can be linked to external aspects (29). The two domains of OxCAP-MH related to the capabilities of appreciating people and nature loaded on a separate, fourth factor, indicating that this concept is supplementary and moves beyond the evaluative space included within the ICECAP-A or EQ-5D-5L instruments. Nevertheless, some domains of both the OxCAP-MH and ICECAP-A loaded on the same factor together with the EQ-5D-5L items. This confirmed the findings of Laszewska et al. (5), namely that the OxCAP-MH indeed measures some aspects of HRQoL and can be considered supplementary rather than complementary to EQ-5D-5L. An interesting finding of the current study is that the “Suitable flat situation” also loaded onto the common factor with EQ-5D-5L, suggesting an association with health. Previous studies exploring EFA between ICECAP-A and EQ-5D measures found that these two instruments share only a few common factors (19, 21). This study confirmed that there is a weak overlap between these two instruments, and only the “Being independent” domain of ICECAP-A loaded on the same factor as the EQ-5D-5L items. These findings suggested that both capability instruments could be considered supplementary rather than complementary to EQ-5D-5L. Nevertheless, if the purpose of the intervention in question is to improve mental health, than a mental health focused measure (e.g. ReQol (59)) could capture these relevant aspects too. Capability instruments capture broader aspects than physical and mental health, but it is currently debatable whether they should be used alongside or supplementary to other measures. The results of the EFA suggested that the both capability instruments captured relevant aspects for common mental health disorders however, the OxCAP-MH seemed to capture further traits which might be relevant to people with severe mental health disorders such as schizophrenic patients with depression.

This analysis found slightly weaker correlations between the capability instruments and the EQ-5D-5L than some of the previous studies conducted in the area of mental health. The OxCAP-MH was compared to the EQ-5D-3L and -5L instruments in a mixed mental health population context and found correlation coefficients between 0.45-0.66 (5, 17). Similar correlations were observed between the ICECAP-A and the EQ-5D instruments when they were compared for opiate dependent patients. The study by Goronitis et al. found that ICECAP-A and EQ-5D-5L have similar construct validity when compared to other clinical measures (23). The slightly different results of the current study confirmed previously identified weaknesses of the EQ-5D-5L instrument to measure HRQoL in severely ill mental health patients (60). Our results also confirmed the findings of a study comparing ICECAP-A and EQ-5D-5L instruments in the area of depression, which concluded that instruments designed specifically to measure depression and mental health explained a greater proportion of the variation in ICECAP-A than the EQ-5D-5L (35). The slightly weaker correlations between capability instruments and EQ-5D-5L could be explained by the specific area of depression in schizophrenia, where evidence has shown that this disease is associated with a higher level of disability in the domain of interpersonal activities, compared to schizophrenic patients without significant depression (61).

In terms of sensitivity to change, the EQ VAS performed better than the EQ-5D-5L based on Spearman's rank correlations between change scores. When comparing the two capability instruments, the ICECAP-A was slightly more correlated with generic measures, whilst the OxCAP-MH was stronger correlated.
with disease-specific measures. These findings are likely to be due to the fact that the OxCAP-MH is a more detailed questionnaire developed within the mental health context and possibly also due to the nature of the underlying scoring concepts, i.e. preference-based versus level sum scores.

The OxCAP-MH and ICECAP-A instruments are both embedded in the capability approach, but they were developed with a different approach, and this study showed that they thereby exhibited somewhat different psychometric properties when deployed on the same patient cohort. A major advantage of using the ICECAP-A in economic evaluations is the availability of its preference-based value set and its shorter length, which reduces the burden for respondents. On the other hand, the OxCAP-MH seems to provide information more closely correlated with mental health-specific aspects. Moreover, the scores of neither capability instruments exhibit floor and ceiling effects, as opposed to the EQ-5D-5L (Appendix 1).

Limitation of this research included a restricted number of data points compared to the number of items. Hence, the robustness of the EFA and the responsiveness analysis may be limited. The study used preference-based index values for two instruments, which can introduce an exogenous source of variance into statistical inference (62). Moreover, relevant value sets for the EQ-5D-5L and the ICECAP-A have different anchor points. The 0 point of the EQ-5D-5L value set is anchored against ‘death’, while the 0 point of the ICECAP-A value set is anchored against ‘no capability’ leading to further potential difficulties in interpreting any comparisons based on preference-weighted scales. Future research should explore further the relationship of preference-based scores once those become available also for the OxCAP-MH instrument investigating also the potential impact of the scale anchor differences between the HRQoL and the capability measures.

A further limitation of this study was the relatively small sample size, which motivated the application of available-case analysis for individual analyses. Establishing the psychometric properties of an instrument is a continuous process and further research should replicate this analysis for a higher number of patients and in other disease areas to strengthen these conclusions and explore potential psychometric differences related to diagnosis. Comparisons of OxCAP-MH and/or ICECAP-A with other capability (e.g. Achieved Capabilities Questionnaire for Community Mental Health (63)) or wellbeing (e.g. ReQol (59)) instruments developed for the area of mental health would further contribute to our understanding of their measurement characteristics. Future research should explore the best method for incorporating capability measures into economic evaluation in the area of mental health (24).

**Conclusion**

The main conclusion of this study is that assessing outcomes in terms of capability for schizophrenic patients with depression provided more relevant, condition-specific information than the EQ-5D-5L or the EQ VAS. The EQ-5D-5L showed less sensitivity to capturing change than the OxCAP-MH and the ICECAP-A instruments. The two capability instruments were more convergent with each other than with any HRQoL measure, confirming the hypothesised more similar underlying ‘capability’ construct. On the other hand, neither proved superior to the other in the current context. Instead, they seem to have different pros and cons. The ICECAP-A and the OxCAP-MH demonstrated similar levels of responsiveness. The ICECAP-A is slightly more strongly correlated with the EQ-5D-5L and the EQ VAS; whilst the OxCAP-MH tends to have stronger correlations than the ICECAP-A with condition-specific instruments due to its mental health specific design. These capability measures provide a viable option for measuring outcome for economic evaluations of severe mental health conditions, and we would recommend the inclusion of OxCAP-MH and/or ICECAP-A alongside generic instruments such as the EQ-5D so that further evidence can be obtained.

**List Of Abbreviations**

BDI; Beck Depression Inventory
EFA: Exploratory Factor Analysis
EQ-5D-5L: Descriptive system of the 5-level EuroQol instrument
EQ VAS: Visual Analogue Scale of the EuroQol instrument
GAD: General Anxiety Disorder
HRQoL: Health-Related Quality of Life
ICECAP-A: ICEpop CAPability measure for Adults
LOWESS: Locally Weighted Scatterplot Smoothing
OxCAP-MH: Oxford CAPabilities questionnaire-Mental Health
RSES: Rosenberg Self-Esteem Scale
WEMWBS: Warwick-Edinburgh Mental Well-being Scale

**Declarations**

Ethics approval and consent to participate: The PoMeT trial received ethical approval from the Berkshire Research Ethics Committee (REC ref 13/SC/0634). All participants provided written consent.
Consent for publication: All authors consent

Availability of data and materials: Not applicable

Funding: The PoMeT trial was funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0712-28021). Joanna Coast is supported by the Wellcome Trust [205384/Z/16/Z].

Author's contributions: TH and JS conceived of the presented idea and developed the conceptual framework of this research. JS provided the resources to this study. TH conducted the analysis with input on different aspects of the study from JC, AL, TS and JS. TH took the lead in writing the manuscript in close consultation with JC, AL, TS and JS. All authors provided critical feedback and helped shape the research, analysis and manuscript. All authors approved the final manuscript.

Acknowledgements: We would like to say thank you to all contributors and participants of the PoMeT trial. We would also like to thank Georg Heinze for his comments on the statistical analyses used in this paper and David Mott who discussed a previous version of this paper at Winter 2020 meeting of the Health Economics Study Group in Newcastle, UK. Finally, we would like to thank the three anonymous reviewers for their insightful comments and helping to shape this manuscript.

Conflict of interest: JC has led the development of the ICECAP measures. JS has led the development of the OxCAP-MH measure. The remaining authors declare that they have no conflict of interest.

References
1. Sen A. Commodities and capabilities. Amsterdam New York New York, N.Y., U.S.A: North-Holland Sole distributors for the U.S.A. and Canada: Elsevier Science Pub. Co. ; 1985.
2. Sen A. Development as freedom: Oxford University Press; 1999.
3. White RG, Imperiale MG, Perera E. The Capabilities Approach: Fostering contexts for enhancing mental health and wellbeing across the globe. Globalization and Health. 2016;12(1).
4. Helter TM CJ, Laszewska A, Stamm T, Simon J. Capability instruments in economic evaluations of health-related interventions – A comparative review of the literature. Quality of Life Research. 2020;29:1433–64.
5. Laszewska A, Schwab, M., Leutner, E. et al. Measuring broader wellbeing in mental health services: validity of the German language OxCAP-MH capability instrument. Qual Life Res. 2019.
6. NICE. Developing NICE guidelines: the manual 2014 (April 2017 update) - Incorporating economic evaluation. National Institute for Health and Clinical Excellence; 2017.
7. Nederlander Z. Guideline for economic evaluations in healthcare 2016 [Available from: https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare.
8. Francis JB, S. SCI's approach to economic evaluation in social care. London: Social Care Institute for Excellence; 2011.
9. Simon JA, P.; Gray, A.; Rugkasa, J., Yeeles, K., Burns, T. Operationalising the capability approach for outcome measurement in mental health research. Social Science & Medicine. 2013;98:187-96.
10. Mulhern B, Mukuria C, Barkham M, Knapp M, Byford S, Soeteman Dr, et al. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. British Journal of Psychiatry. 2014;205(3):236-43.
11. Halling Hastrup L, Nordentoft M, Hjorthøj C, Gyrd-Hansen D. Does the EQ-5D measure quality of life in schizophrenia? J Ment Health Policy Econ. 2011;14(4):187-96.
12. Koç M, Tel H, Karakülah K. Determining care burden and psychiatric symptom level in caregiver of schizophrenia patient. Perspectives in Psychiatric Care.n/a(n/a).
13. Wander C. Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The American journal of managed care. 2020;26(3 Suppl):S62-s8.
14. Steel C, Korrelboom K, Fazil Baksh M, Kingdon D, Simon J, Wykes T, et al. Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial. Behaviour Research and Therapy. 2020;135:103734.
15. Steel C, van der Gaag M, Korrelboom K, Simon J, Phiri P, Baksh MF, et al. A randomised controlled trial of positive memory training for the treatment of depression within schizophrenia. BMC Psychiatry. 2015;15(1).
16. Upthegrove R, Marwaha S, Birchwood M. Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? Schizophrenia Bulletin. 2016;43(2):240-4.

17. Verghese F, Jenkinson C, Burns T, Anand P, Gray A, Rugkäsä J, et al. Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH). Health and Quality of Life Outcomes. 2017;15(1).

18. Al-Janabi H, Peters TJ, Brazier J, Bryan S, Flynn TN, Clemens S, et al. An investigation of the construct validity of the ICECAP-A capability measure. Quality of life research : an international journal of quality aspects of treatment, care and rehabilitation. 2013;22(7):1831-40.

19. Davis JC, Liu-Ambrose T, Richardson CG, Bryan S. A comparison of the ICECAP-O with EQ-5D in a falls prevention clinical setting: are they complements or substitutes? Quality of Life Research. 2013;22(5):969-77.

20. Keeley T, Al-Janabi H, Lorgelly P, Coast J. A qualitative assessment of the content validity of the ICECAP-A and EQ-5D-SL and their appropriateness for use in health research. PLoS ONE. 2013;8(12).

21. Keeley T, Coast J, Nicholls E, Foster NE, Jowett S, Al-Janabi H. An analysis of the complementarity of ICECAP-A and EQ-5D-3 L in an adult population of patients with knee pain. Health and Quality of Life Outcomes. 2016;14(1).

22. Goranitis I, Coast J, Al-Janabi H, Latthe P, Roberts TE. The validity and responsiveness of the ICECAP-A capability-well-being measure in women with irritable lower urinary tract symptoms. Quality of Life Research. 2016;25(8):2063-75.

23. Goranitis I, Coast J, Day E, Copello A, Freemantle N, Seddon J, et al. Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. Value in Health. 2016;19(6):820-8.

24. Simon J. MS, Laszewska A, Yeeles K, Burns T, Gray A .. Cost and quality-of-life impacts of community treatment orders (CTOs) for patients with psychosis: Economic evaluation of the OCTET trial. Social Psychiatry and Psychiatric Epidemiology. 2020.

25. Al-Janabi HF, T. N.; Coast, J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Quality of Life Research. 2012;21(1):167-76.

26. Laszewska A, Österle A, Wancata J, Simon J. Prevalence of mental diseases in Austria : Systematic review of the published evidence. Wien Klin Wochenschr. 2018;130(3-4):141-50.

27. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.

28. Simon J, Laszewska A, Leutner E, Spiel G, Churchman D, Mayer S. Cultural and linguistic transferability of the multi-dimensional OxCAP-MH capability instrument for outcome measurement in mental health: The German language version. BMC Psychiatry. 2018;18(1).

29. Helter TM Kl, Kanka A, Varga O, Kalman J, Simon J. Internal and external aspects of freedom in the application of the capability approach – the case study of developing a linguistically and culturally valid Hungarian version of the OxCAP-MH well-being questionnaire. unpublished manuscript.

30. Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, et al. Scoring the Icecap-a Capability Instrument. Estimation of a UK General Population Tariff. Health Economics. 2015;24(3):258-69.

31. Chen G, Ratcliffe J, Kaambwa B, McCaffrey N, Richardson J. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. Soc Indic Res. 2018;140(1):175-90.

32. Linton MJ, Mitchell PM, Al-Janabi H, Schlander M, Richardson J, Lezzi A, et al. Comparing the German Translation of the ICECAP-A Capability Wellbeing Measure to the Original English Version: Psychometric Properties across Healthy Samples and Seven Health Condition Groups. Appl Res Qual Life. 2018.

33. Khan MA, Richardson J. Variation in the apparent importance of health-related problems with the instrument used to measure patient welfare. Quality of Life Research. 2018;27(11):2885-96.

34. Keeley T, Al-Janabi H, Nicholls E, Foster NE, Jowett S, Coast J. A longitudinal assessment of the responsiveness of the ICECAP-A in a randomised controlled trial of a knee pain intervention. Quality of Life Research. 2015;24(10):2319-31.

35. Mitchell PM, Al-Janabi H, Byford S, Kuyken W, Richardson J, Lezzi A, et al. Assessing the validity of the ICECAP-A capability measure for adults with depression. BMC Psychiatry. 2017;17(1).

36. Tang C, Xiong Y, Wu H, Xu J. Adaptation and assessments of the Chinese version of the ICECAP-A measurement. Health and Quality of Life Outcomes. 2018;16(1).

37. Birmingham Uo. ICECAP-A 2019 [Available from: https://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/HE/ICECAP/ICECAP-A/index.aspx.

38. Afentou N, Kinghorn P. A Systematic Review of the Feasibility and Psychometric Properties of the ICEpopCAPability Measure for Adults and Its Use So Far in Economic Evaluation. Value in Health. 2020;23(4):515-26.

39. Payakachat N, Ali MM, Tilford JM. Can The EQ-5D Detect Meaningful Change? A Systematic Review. PharmacoEconomics. 2015;33(11):1137-54.

40. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.

41. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20(10):1727-36.

42. Foundation ER. 2019 [Available from: https://euroqol.org/eq-5d-instruments/eq-5d-si-about/valuation-standard-value-sets/.

43. N. D. 5 Things You Should Do with EQ-5D Data 2016 [Available from: https://www.ohe.org/news/5-things-you-should-do-eq-5d-data.

44. Association AP. Diagnostic and statistical manual of mental disorders. 4th ed text revision ed. Washington, DC: American Psychiatric Association; 2000.

45. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.

46. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):371-25.
47. Rosenberg M. Society and the adolescent self-image. Princeton, NJ: Princeton University Press; 1965.
48. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007;5:63.
49. Wilcoxon F. Individual comparisons by ranking methods. Biom Bull 1 (6): 80–83. JSTOR; 1945.
50. Mann HB, Whitney DR. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other. Ann Math Statist. 1947;18(1):50-60.
51. Kruskal WH, Wallis WA. Use of Ranks in One-Criterion Variance Analysis. Journal of the American Statistical Association. 1952;47(260):583-621.
52. Streiner DL, Norman, G. R., & Cairney, J. . Health measurement scales: A practical guide to their development and use. Oxford Oxford University Press; 2015.
53. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539-49.
54. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd ed). 1988.
55. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. Journal of the American Statistical Association. 1979;74(368):829-36.
56. Franklin M, Mukuria C, Mulhen B, Tran I, Brazier J, Watson S. Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity. The Patient - Patient-Centered Outcomes Research. 2019;12(4):405-17.
57. Thompson B, Daniel LG. Factor Analytic Evidence for the Construct Validity of Scores: A Historical Overview and Some Guidelines. Educational and Psychological Measurement. 1996;56(2):197-208.
58. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. Journal of Clinical Epidemiology. 2000;53(5):459-68.
59. Keetharuth AD, Brazier J, Connell J, Bjorner JB, Carlton J, Taylor Buck E, et al. Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. The British journal of psychiatry : the journal of mental science. 2018;212(1):42-9.
60. Brazier J. Is the EQ–5D fit for purpose in mental health? British Journal of Psychiatry. 2010;197(5):348-9.
61. B. N S, Grover S. Depression in schizophrenia: Prevalence and its impact on quality of life, disability, and functioning. Asian Journal of Psychiatry. 2020;54:102425.
62. Parkin D, Rice N, Devlin N. Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? Med Decis Making. 2010;30(5):556-65.
63. Sacchetto B, Aguiar R, Vargas-Moniz MJ, Jorge-Monteiro MF, Neves MJ, Cruz MA, et al. The capabilities questionnaire for the community mental health context (CQ-CMH): A measure inspired by the capabilities approach and constructed through consumer-researcher collaboration. Psychiatric Rehabilitation Journal. 2016;39(1):55-61.

Tables

Table 1 Patient characteristics and mean baseline OxCAP-MH, ICECAP-A, EQ-5D-5L and EQ VAS scores
| Scale (Min-Max)       | Overall data | OxCAP-MH (0-100) | ICECAP-A (0-1) | EQ-5D-5L (-0.218-1) | EQ VAS (0-100) |
|----------------------|-------------|-----------------|----------------|---------------------|----------------|
|                      | N  | %  | n  | Mean (SD) | N  | Mean (SD) | N  | Mean (SD) | N  | Mean (SD) |
| **Gender**           |    |    |    |           |    |           |    |           |    |           |
| Male                 | 75 | 75%| 69 | 56.46 (12.25) | 72 | 0.529 (0.224) | 75 | 0.641 (0.254) | 74 | 52.48 (2.39) |
| Female               | 25 | 25%| 24 | 53.39 (14.65) | 25 | 0.513 (0.168) | 25 | 0.600 (0.303) | 25 | 43.20 (4.40) |
| **Higher education** |    |    |    |           |    |           |    |           |    |           |
| Yes                  | 49 | 49%| 46 | 53.36 (1.93) | 47 | 0.507 (0.201) | 49 | 0.616 (0.294) | 49 | 48.91 (3.16) |
| No                   | 51 | 51%| 47 | 57.91 (1.81) | 50 | 0.542 (0.220) | 51 | 0.643 (0.239) | 51 | 51.29 (2.89) |
| **Living situation** |    |    |    |           |    |           |    |           |    |           |
| Living with family   | 19 | 19%| 19 | 51.48 (13.20) | 19 | 0.488 (0.168) | 19 | 0.702 (0.165) | 19 | 57.89 (18.05) |
| Renting a flat       | 12 | 12%| 10 | 59.06 (16.38) | 10 | 0.520 (0.226) | 12 | 0.649 (0.260) | 11 | 46.73 (20.24) |
| Owning a flat        | 5  | 5% | 4  | 51.95 (5.90)  | 5  | 0.524 (0.157) | 5  | 0.488 (0.268) | 5  | 43.40 (21.63) |
| Other                | 64 | 64%| 60 | 56.67 (12.41) | 63 | 0.537 (0.226) | 64 | 0.616 (0.289) | 64 | 48.95 (22.03) |
| **Employment**       |    |    |    |           |    |           |    |           |    |           |
| Employed full-time   | 3  | 3% | 3  | 67.19 (14.32) | 3  | 0.675 (0.122) | 3  | 0.682 (0.219) | 3  | 55.00 (18.03) |
| Employed part-time   | 9  | 9% | 8  | 59.18 (9.21)  | 8  | 0.580 (0.113) | 9  | 0.658 (0.283) | 8  | 52.13 (20.01) |
| Unemployed           | 86 | 86%| 80 | 55.22 (13.00) | 84 | 0.516 (0.220) | 86 | 0.639 (0.256) | 86 | 50.60 (21.08) |
| Other (Student/Retired) | 2 | 2% | 2  | 42.19 (8.84)  | 2  | 0.445 (0.100) | 2  | 0.047 (0.028) | 2  | 15.00 (14.14) |
| **Primary diagnosis**|    |    |    |           |    |           |    |           |    |           |
| Schizophrenia        | 70 | 70%| 66 | 56.72 (12.77) | 68 | 0.521 (0.216) | 70 | 0.635 (0.274) | 70 | 51.19 (2.48) |
| Schizoaffective or psychosis NOS** | 30 | 30%| 27 | 53.07 (2.52)  | 29 | 0.533 (0.201) | 30 | 0.618 (0.251) | 29 | 47.59 (4.15) |
| Depression severity  |    |    |    |           |    |           |    |           |    |           |
| Mild/moderate        | 41 | 41%| 40 | 63.44 (1.58)  | 41 | 0.646 (0.152) | 41 | 0.720 (0.231) | 41 | 56.56 (3.17) |
| High                 | 59 | 59%| 53 | 49.80 (1.61)  | 56 | 0.436 (0.204) | 59 | 0.567 (0.272) | 58 | 45.59 (2.73) |
| Intervention         |    |    |    |           |    |           |    |           |    |           |
| Treatment            | 49 | 49%| 46 | 55.10 (12.59) | 49 | 0.534 (0.209) | 51 | 0.608 (0.246) | 50 | 47.95 (2.73) |
| Control group        | 51 | 51%| 47 | 56.22 (13.30) | 48 | 0.516 (0.213) | 49 | 0.653 (0.286) | 49 | 52.37 (3.26) |

*Wilcoxon rank-sum test for two-group comparison, Kruskal–Wallis one-way ANOVA for multiple group comparison**NOS: Not Otherwise Specified

Table 2. Baseline scores of the relevant outcome measures used in the trial and the associated Spearman’s rank correlations
|                | N  | Mean | SD  | Min  | Max  | Theoretical Min-Max | with OxCAP-MH n | Coef. | p value* | with ICECAP-A n | Coef. | p value* | with EQ-5D-5L n | Coef. | p value* | with EQ VAS n | Coef. | p value* | with BDI n | Coef. | p value* |
|----------------|----|------|-----|------|------|---------------------|-----------------|-------|----------|-----------------|-------|----------|----------------|-------|----------|-------------|-------|----------|
| OxCAP-MH       | 93 | 55.66| 12.90| 21.9 | 87.5 | 0-100               |                 |       |          |                 |       |          |                 |       |          |             |       |          |
| ICECAP-A       | 97 | 0.525| 0.211| 0.077| 0.978| 0-1                 | 92              | 0.677 | 0.000    |                 |       |          |                 |       |          |             |       |          |
| EQ-5D-5L       | 100| 0.630| 0.266| -0.218| 1    | -0.218-1            | 93              | 0.406 | 0.000    | 97              | 0.364 | 0.000    | 93             | 0.406 | 0.000    | 97          | 0.364 | 0.000    |
| EQ VAS         | 99 | 50.14| 21.19| 3     | 95   | 0-100               | 93              | 0.354 | 0.001    | 97              | 0.431 | 0.000    | 99             | 0.486 | 0.000    | 99          | 0.486 | 0.000    |
| BDI            | 100| 30.45| 9.99 | 14    | 52   | 0-63                | 93              | -0.551| 0.000    | 97              | -0.505| 0.000    | 100            | -0.316| 0.001    | 99          | -0.316| 0.001    |
| GAD            | 100| 11.16| 5.62 | 0     | 21   | 0-21                | 93              | -0.481| 0.000    | 97              | -0.584| 0.000    | 100            | -0.497| 0.000    | 99          | -0.497| 0.000    |
| RSES           | 100| 28.50| 5.48 | 14    | 40   | 10-40               | 93              | -0.619| 0.000    | 97              | -0.558| 0.000    | 100            | -0.270| 0.007    | 99          | -0.270| 0.007    |
| WEMWBS         | 100| 34.25| 10.54| 14    | 65   | 14-70               | 93              | 0.718 | 0.000    | 97              | 0.716 | 0.000    | 100            | 0.242 | 0.015    | 99          | 0.242 | 0.015    |

BDI: Beck Depression Inventory; GAD: General Anxiety Disorder; RSES: Rosenberg Self-Esteem Scale; WEMWBS: Warwick-Edinburgh Mental Well-Being Scale; Moderate correlations (0.3-0.5) in italic, Strong correlations (>=0.5) in bold; *Wilcoxon matched pairs signed rank test

Table 3 Exploratory factor analysis of the OxCAP-MH, ICECAP-A and EQ-5D-5L items with 4 factors using promin rotation.
### Table 4: Spearman's rank correlations between change scores of OxCAP-MH, ICECAP-A and EQ-5D-5L and EQ VAS scores

|                      | Factor 1 | Factor 2 | Factor 3 | Factor 4 |
|----------------------|----------|----------|----------|----------|
| **OxCAP-MH**         |          |          |          |          |
| Limit daily activities | 0.453    |          |          |          |
| Meet socially with friends or family |          | 0.646    |          |          |
| Less sleep over worries | 0.523    |          |          |          |
| Enjoy free time activities |          | 0.584    |          |          |
| Suitable fat situation | 0.391    |          |          |          |
| Safety in neighbourhood |          | 0.411    |          |          |
| Probability of assault | 0.513    |          |          |          |
| Probability of discrimination |          | 0.635    |          |          |
| Local decisions |          |          | 0.517    |          |
| Freedom of expression |          | 0.384    |          |          |
| Appreciation of nature |          |          |          | 0.688    |
| Respect for people around |          |          | 0.786    |          |
| Enjoy love and support |          | 0.381    | 0.562    |          |
| Freedom of deciding for yourself |          | 0.510    | 0.494    |          |
| Creativity |          |          |          | 0.498    |
| Access to interesting activities/employment |          | -0.513   | 0.752    |          |
| **ICECAP-A**         |          |          |          |          |
| Feeling settled and secure |          | 0.499    | 0.404    |          |
| Love, friendship and support |          |          | 0.725    |          |
| Being independent |          |          | 0.385    |          |
| Achievement and progress |          |          | 0.598    |          |
| Enjoyment and pleasure |          |          |          | 0.812    |
| **EQ-5D-5L**         |          |          |          |          |
| Mobility |          |          |          | 0.928    |
| Self-care |          |          |          | 0.806    |
| Daily activities |          |          |          | 0.754    |
| Pain/discomfort |          |          |          | 0.761    |
| Anxiety/Depression |          |          |          | 0.389    |

*Loadings ≤0.35 were removed*
|                          | OxCAP-MH | ICECAP-A | EQ-5D-5L |   | EQ VAS |   |
|--------------------------|----------|----------|----------|---|--------|---|
|                          | n  | Coef | p value* | n | Coef | p value* | n | Coef | p value* | n | Coef | p value* |
| OxCAP-MH                 |    |      |          |    |       |           |    |       |           |    |       |           |
| ICECAP-A                 | 78 | 0.388 | 0.000    |    |       |           |    |       |           |    |       |           |
| EQ-5D-5L                 | 79 | 0.131 | 0.250    | 88 | 0.247 | 0.020    |    |       |           |    |       |           |
| EQ VAS                   | 79 | 0.203 | 0.391    | 88 | 0.269 | 0.011    | 90 | 0.333 | 0.001    |    |       |           |
| Beck Depression Inventory (BDI) | 79 | -0.437 | 0.000    | 88 | -0.355 | 0.001    | 94 | -0.178 | 0.087    | 90 | -0.198 | 0.000    |
| Generalized Anxiety Disorder scale (GAD) | 79 | -0.557 | 0.000    | 88 | -0.451 | 0.000    | 94 | -0.217 | 0.038    | 90 | -0.272 | 0.015    |
| Rosenberg Self-Esteem Scale (RSES) | 79 | -0.440 | 0.000    | 87 | -0.387 | 0.000    | 91 | -0.208 | 0.048    | 89 | -0.250 | 0.000    |
| Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) | 79 | 0.493 | 0.837    | 88 | 0.385 | 0.000    | 91 | 0.152 | 0.150    | 89 | 0.270 | 0.264    |

Moderate correlations (0.3-0.5) in italic, Strong correlations (>=0.5) in bold; * Wilcoxon matched pairs signed rank test

**Figures**

![Scatterplots and LOWESS lines](image1)

**Figure 1**

- a Scatterplots and LOWESS lines for OxCAP-MH vs ICEAP-A change scores
- b Scatterplots and LOWESS lines for OxCAP-MH vs EQ-5D-5L change scores
- c Scatterplots and LOWESS lines for OxCAP-MH vs EQ VAS change scores
- d Scatterplots and LOWESS lines for ICECAP-A and EQ-5D-5L change scores
- e Scatterplots and LOWESS lines for ICECAP-A and EQ VAS change scores
- f Scatterplots and LOWESS lines for EQ-5D-5L and EQ VAS change scores

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarymaterial23122020.pdf